David Shaw’s MaxCyte MXCT Stock Holding History

David Shaw’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200,505	Closed	-$141K	–	5092
2026 Q1	$141K	Sell	200,505 -463,451	-70%	-$433K	﹤0.01%	4248
2025 Q4	$1.03M	Buy	663,956 +366,317	+123%	+$585K	﹤0.01%	3518
2025 Q3	$470K	Buy	297,639 +276,087	+1,281%	+$480K	﹤0.01%	3893
2025 Q2	$47K	Sell	21,552 -60,212	-74%	-$146K	﹤0.01%	4174
2025 Q1	$223K	Sell	81,764 -26,837	-25%	-$106K	﹤0.01%	3890
2024 Q4	$452K	Buy	108,601 +84,105	+343%	+$318K	﹤0.01%	3675
2024 Q3	$95.3K	Buy	+24,496	New	+$103K	﹤0.01%	4255
2023 Q4	–	Sell	-25,162	Closed	-$78.5K	–	4492
2023 Q3	$78.5K	Sell	25,162 -23,420	-48%	-$94.2K	﹤0.01%	3877
2023 Q2	$223K	Sell	48,582 -17,626	-27%	-$81K	﹤0.01%	3710
2023 Q1	$328K	Buy	+66,208	New	+$326K	﹤0.01%	3722
2022 Q2	–	Sell	-45,109	Closed	-$315K	–	5610
2022 Q1	$315K	Buy	+45,109	New	+$308K	﹤0.01%	4626

Other funds holding MXCT

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $128M AUM

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

David Shaw's MXCT Position: Q2 2026 in Review

David Shaw sold out of MaxCyte (MXCT) in Q2 2026, closing a stake of 200,505 shares — an estimated $141K sold.

David Shaw first reported a position in MXCT in Q1 2022 and held it in 11 quarters. The position peaked at $1.03M in Q4 2025. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

David Shaw reported no remaining MaxCyte position as of Q2 2026 after selling out during the quarter.
David Shaw sold 200,505 MaxCyte shares in Q2 2026, an estimated $141K.
David Shaw first reported a position in MaxCyte in Q1 2022 and held it in 11 quarters.
David Shaw's MaxCyte position peaked at $1.03M in Q4 2025.
123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.